Back to Search
Start Over
Drug Development for Transthyretin Amyloidosis: Time to Fix the System?
- Source :
-
JACC. Case reports [JACC Case Rep] 2024 Aug 07; Vol. 29 (15), pp. 102414. Date of Electronic Publication: 2024 Aug 07 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Competing Interests: The authors received no funding support for this article. Dr Fine has received consulting honoraria from Pfizer, Alnylam, Eidos/BridgeBio, AstraZeneca, Ionis, NovoNordisk, Janssen, Sanofi. Dr Witteles has received consulting and advisory honoraria from Pfizer, Alnylam, BridgeBio, Astra Zeneca, Novo Nordisk, and Alexion.
Details
- Language :
- English
- ISSN :
- 2666-0849
- Volume :
- 29
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- JACC. Case reports
- Publication Type :
- Editorial & Opinion
- Accession number :
- 39157559
- Full Text :
- https://doi.org/10.1016/j.jaccas.2024.102414